Provision of information on regulatory authorities' websites

Internal Medicine Journal

Volumn 38, Issue 7, 2008, Pages 559-567

  Vitry, A ^a   Lexchin, J ^c   Sasich, L ^d   Dupin Spriet, T ^e   Reed, T ^f   Bertele, V ^g   Garattini, S ^g   Toop, L ^h   Hurley, E ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Australian Medicines Handbook ^*  (Australia)

^c YORK UNIVERSITY   (Canada)

^d LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^e UNIV LILLE   (France)

^f Vancouver BC   (Netherlands)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Access to information; Internet; Medicine; Regulatory agency

Indexed keywords

ARTICLE; AUSTRALIA; AUTHORITY; CANADA; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; FRANCE; INFORMATION SYSTEM; INTERNET; NEW ZEALAND; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUSTRALIA; CANADA; DISCLOSURE; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HUMANS; INTERNET; NEW ZEALAND; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41749092580     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01588.x     Document Type: Article

References (22)

1. Statement of the International Working Group on Transparency and Accountability in Drug Regulation. Amsterdam : Health Action International 1996. Available from http://www.haiweb.org/pubs/sec-sta.html
2. Lexchin J, Mintzes B. Transparency in drug regulation: mirage or oasis? CMAJ 2004 171 : 1363 5.
3. Editorial Executive Committee. Transparency - in the eye of the beholder? Aust Prescr 2005 28 : 83 4.
4. Abraham J, Lewis G. Secrecy and transparency of medicines licensing in the EU. Lancet 1998 352 : 480 82.
5. Les agences du médicament vont devoir s'y faire: l'opacité, c'est fini! Rev Prescr 2004 24 : 145.
6. World Health Organization. Pharmaceuticals and the Internet: drug regulatory authorities. Geneva : World Health Organisation, 2001 cited 14 Dec 2007 Available from URL : http://healthtech.who.int/tbs/qual/h296e.pdf
7. Drugs agencies' websites under scrutiny. Prescr Intern 2001 55 : 157.
8. Funding of medicines agencies. Prescr Intern 2000 9 : 34.
9. L'agence française des produits de santé est-elle avant tout au service des patients, ou au service des firmes pharmaceutiques. Rev Prescr 2005 266 : 793 6.
10. Frost A. The United States Freedom of Information Act: lessons learned from thirty years of experience with the law. Public Citizen's Freedom of Information Clearinghouse. Available from : http://www.citizen.org/litigation/ free_info/articles.cfm?ID=6127
11. How the industries stack up: most profitable industries. Fortune April 18 F 28.
12. Nissen S, Wolski K, Topol E. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005 294 : 2581 6.
13. De Angelis CD, Drazen JM, Frizzle FA, Haug C, Hoey J, Horton R et al. Is this clinical trial fully registered - a statement from the international committee of medical journal editors. N Engl J Med 2005 352 : 436 8.
14. Garattini S. EMEA: for patients or for industry. Pharmacoeconomics 2005 23 : 207 8.
15. Lexchin J. Secrecy and the health protection branch. CMAJ 1998 159 : 481 3.
16. Burke K. NICE accuse drug companies of withholding data. BMJ 2002 324 : 320.
17. Public Citizen's Health Research Group. Letter to the FDA concerning the unresponsiveness of the agency's Freedom of Information Office to our requests. 2001 May cited 14 Dec 2007 Available from URL : http://www.citizen.org/ publications/release.cfm?ID=6773
18. International Society of Drug Bulletins. Assessment of nine European Public Assessment Reports published by the European medicines evaluation agency (EMEA2). London : ISDB 1998.
19. International Society of Drug Bulletins. The failings of the European Medicines Evaluation Agency. ISDB Newsletter 2001 15 : 11 13 cited 14 Dec 2007 Available from URL : http://66.71.191.169/isdbweb/pag/documents/Febru2001.pdf
20. National Prescribing Service Summit: informing judgments about medicines. 7 9 Sept 2005. Final report. National Prescribing Service Surry Hills cited 14 Dec 2007 Available from URL : http://www.nps.org.au/resources/content/ nps_summit_report_2005.pdf
21. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union 2004 30 April: L 136/34-36/57.
22. Joint declaration by HAI Europe, the ISDB, BEUC, the AIM and the Medicines in Europe Forum. Relevant information for empowered citizens. 2006 Oct cited 14 Dec 2007 Available from URL : http://www.isdbweb.org/pag/documents/ relevant_health_information_000.pdf